The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
Moderna, Inc. may be engaged in a once-in-a-biotech’s-lifetime challenge to develop a COVID-19 vaccine, but that does not mean it is not looking ahead to other opportunities.
The company signed two early stage deals on 16 September which together generate $100m upfront revenues - one an expansion of an existing collaboration with cystic fibrosis (CF) specialist Vertex, and
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
